A phase II clinical trial of celecoxib combined with platinum-based chemotherapy in the treatment of patients with advanced NSCLC as first-line treatment

Chinese Journal of Lung Cancer

Volumn 11, Issue 3, 2008, Pages 425-430

  Wang, Zhijie ^a   Duan, Jianchun ^b   Guo, Qingzhi ^b   Wei, Zhigang ^b   Xue, Weicheng ^b   Wu, Meina ^b   Zhao, Jun ^b   Yang, Lu ^b   An, Tongtong ^b   Liu, Xuyi ^b   Wang, Jie ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^b NONE

Author keywords

Chemotherapy; Cyclooxygenase 2 inhibitors; Lung neoplasms

Indexed keywords

ANTINEOPLASTIC AGENT; CELECOXIB; CISPLATIN; CYCLOOXYGENASE 2; DOCETAXEL; GEMCITABINE; OVELBINE; PLATINUM;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; FEMALE; HEART ARRHYTHMIA; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LIVER INJURY; LUNG NON SMALL CELL CANCER; MALE; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

EID: 47149100928     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: 10.3779/j.issn.1009-3419.2008.03.031     Document Type: Article

References (21)

1. Proceedings of the european consensus conference on medical treatment of non-small cell lung cancer. Lung Cancer, 2002, 38(suppl 3): S1-85.
2. Bunn PA Jr, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res, 1998, 4(5): 1087-1100.
3. Dempke W, Rie C, Grothey A, et al. Cyclooxygenase-2: a novel target for cancer therapy? J Cancer Res Clin Oncol, 2001, 127(7): 411-417.
4. Castelao JE, Robert DB. Lung cancer and cyclooxygenase-2. Ann Thorac Surg, 2003, 76(4): 1327-1335.
5. Zhang H, Sun XF. Overexpression of cyclooxygenase-2 correlates with advanced stages of colorectal cancer. AJG, 2002, 97(4): 1037-1041.
6. Shirahama T, Sakakura C. Overexpression of cyclooxygenase-2 in squamous cell carcinoma of the urinary bladder. Clin Cancer Res, 2001, 7(3): 558-561.
7. Shim JY, An HJ, Lee YH, et al. Overexpression of cyclooxygenase-2 is associated with breast carcinoma and its poor prognostic factors. Mod Pathol, 2003, 16(12): 1199-1204.
8. Wolff H, Saukkonen SA, Karjalainen A, et al. Expression ofcyclooxygenase-2 in human lung carcinoma. Cancer Res, 1998, 58(22): 4997-5001.
9. Petkova DK, Clelland C, Ronan J, et al. Overexpression of cyclooxygenase-2 in non-small cell lung cancer. Respir Med, 2004, 98(2): 164-172.
10. Achiwa H, Yatabe Y, Hida T, et al. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res, 1999, 5(5): 1001-1005.
11. Francis WN, Wilson CM, Stephen G, et al. Docetaxel and cyclooxygenase-2 inhibition with celecoxib for advanced non-small cell lung cancer progressing after platinum-based chemotherapy: a multicenter phase II trial. Lung Cancer, 2005, 48(4): 267-273.
12. Joanne RB, Raymond ND. Cyclooxygenase as a target in lung cancer. Clin Cancer Res, 2004, 10(supp 1): 4266-4269.
13. Liao ZX, Ritsuko K, Luka M, et al. A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patientswith unfavorable performance status inoperable/unresectable non-small cell lung cancer. Clin Cancer Res, 2005, 11(9): 3342-3348.
14. Altorki NK, Keresztes RS, Port JL, et al. Celecoxib, a selective cyclooxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J Clin Oncol, 2003, 21(14): 2645-2650.
15. Zhou SW, Zhou CC, Xu JF, et al. First-line regimen of vinorelbine and cisplatin(NP) combined with cyclooxygenase-2 inhibitor celecoxib in advanced non-small-cell lung cancer. J Tongji Uni (Med Sci), 2007, 28(5): 87-90.
16. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med, 2002, 346(2): 92-98.
17. Georgoulias V, Ardavanis A, Tsiafaki X, et al. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol, 2005, 23(13): 2882-2883.
18. Martoni A, Marino A, Sperandi F, et al. Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer. Eur J Cancer, 2005, 41(1): 81-92.
19. Gao Y, Shi ZQ, Cao CW, et al. A randomized trial of docetaxol plus cisplatin versus gemzar plus cisplatin in treating advanced non-small cell lung cancer. Ai Zheng, 2005, 24(8): 985-989.
20. Maxwell SR, Webb DJ. COX-2 selective inhibitors - important lessons learned. Lancet, 2005, 365(9458): 449-451.
21. Scott DS, John VM, Marc AP, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med, 2005, 352(11): 1071-1080.